BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khoja S, Huynh N, Warnecke AMP, Asatryan L, Jakowec MW, Davies DL. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl) 2018;235:1697-709. [PMID: 29500584 DOI: 10.1007/s00213-018-4869-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Silva J, Carry E, Xue C, Zhang J, Liang J, Roberge JY, Davies DL. A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice. Molecules 2021;26:1791. [PMID: 33810134 DOI: 10.3390/molecules26061791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. [PMID: 32360480 DOI: 10.1016/j.phrs.2020.104859] [Cited by in Crossref: 226] [Cited by in F6Publishing: 203] [Article Influence: 113.0] [Reference Citation Analysis]
3 Reyes-Espinosa F, Nieto-Pescador MG, Bocanegra-García V, Lozano-Guzmán E, Rivera G. In Silico Analysis of FDA Drugs as P2X4 Modulators for the Treatment of Alcohol Use Disorder. Mol Inform 2020;39:e1900111. [PMID: 32511896 DOI: 10.1002/minf.201900111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Melbourne JK, Thompson KR, Peng H, Nixon K. Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders. Prog Mol Biol Transl Sci 2019;167:179-221. [PMID: 31601404 DOI: 10.1016/bs.pmbts.2019.06.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
5 Getachew B, Tizabi Y. Antidepressant effects of moxidectin, an antiparasitic drug, in a rat model of depression. Behav Brain Res 2019;376:112220. [PMID: 31513828 DOI: 10.1016/j.bbr.2019.112220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Warnecke AMP, Kang MS, Jakowec MW, Davies DL. The macrocyclic lactones ivermectin and moxidectin show differential effects on rotational behavior in the 6-hydroxydopamine mouse model of Parkinson's disease. Behav Brain Res 2020;393:112804. [PMID: 32668263 DOI: 10.1016/j.bbr.2020.112804] [Reference Citation Analysis]
7 Silva J, Khoja S, Asatryan L, Pacifici E, Davies DL. A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice. Alcohol 2020;86:1-8. [PMID: 32278067 DOI: 10.1016/j.alcohol.2020.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Bragança B, Correia-de-Sá P. Resolving the Ionotropic P2X4 Receptor Mystery Points Towards a New Therapeutic Target for Cardiovascular Diseases. Int J Mol Sci 2020;21:E5005. [PMID: 32679900 DOI: 10.3390/ijms21145005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 El-Saber Batiha G, Alqahtani A, Ilesanmi OB, Saati AA, El-Mleeh A, Hetta HF, Magdy Beshbishy A. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals (Basel) 2020;13:E196. [PMID: 32824399 DOI: 10.3390/ph13080196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]